Edaravone PCD Pharma Franchise Company
Cafoli Lifecare offers a specialised Edaravone PCD pharma franchise centred on an injectable formulation manufactured at WHO-GMP certified facilities. This gives franchise partners access to a high-value neurology molecule for hospital and critical-care channels.
What is Edaravone?
Edaravone is a free-radical scavenger (antioxidant) that reduces oxidative stress-induced neuronal damage. It is used as a neuroprotective agent in acute ischaemic stroke and, in many markets, to slow functional decline in amyotrophic lateral sclerosis (ALS). Read its profile on PubChem.
Therapeutic Applications
Edaravone injection is used in the acute management of ischaemic stroke to limit neuronal injury and in the treatment of ALS to slow the loss of physical function. It is administered in hospital and specialist settings under close supervision. Prescriptions come from neurologists, stroke physicians and intensivists.
Why Edaravone is a High-Potential Molecule for Distributors
Edaravone is a premium, specialist neuroprotective agent with limited competition and a high per-unit value, so even modest volumes deliver strong margins. Rising stroke incidence and growing ALS awareness are expanding its institutional use. Because it is administered in hospitals, a distributor who secures tenders and neurology accounts gains a defensible, high-value niche.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- PubChem: Edaravone
- PubMed: Edaravone literature
Our formulations of Edaravone find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: